Alessio Nahmad – VJRegenMed https://mirror.vjregenmed.com The Video Journal of Regenerative Medicine Thu, 28 Apr 2022 08:38:46 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.2 https://d2xz56kaqxj8if.cloudfront.net/wp-content/uploads/2023/09/12102509/VJR-Favicon.png Alessio Nahmad – VJRegenMed https://mirror.vjregenmed.com 32 32 The use of CRISPR-Cas9 technology in the development of T cell therapies https://mirror.vjregenmed.com/video/qiwwheyhxpw-the-use-of-crispr-cas9-technology-in-the-development-of-t-cell-therapies/ Fri, 01 Apr 2022 12:36:55 +0000 http://13.40.107.223/video/qiwwheyhxpw-the-use-of-crispr-cas9-technology-in-the-development-of-t-cell-therapies/ Alessio Nahmad, PhD, Tel Aviv University, Tel Aviv, Israel, describes the role and applications of CRISPR-Cas9-based genome editing in the development of CAR T-cell and T cell receptor (TCR) therapies. The aim is often to ablate specific genes that can reduce efficiency of the T cell product such the TCR genes. For example, ablating TCR genes can improve efficiency and reduce toxicity. In addition, ablating certain genes, such as PD-1, can reduce cellular exhaustion. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.

]]>